Duality Biologics, a developer of novel modality drugs operating in the United States and China, has announced a technology license agreement with Denmark-based Adcendo ApS. Under the agreement, Adcendo has been granted a license to use Duality’s antibody drug conjugate (ADC) platform, DITAC, in its mesenchymal tumor product uPARAP program. In return, Adcendo will pay an undisclosed upfront fee, milestone payments, and tiered royalties.
Company Overview and Pipeline
Founded in January 2020, Duality Biologics focuses on oncology and autoimmune diseases, boasting a product pipeline consisting of over 10 best-in-class and first-in-class bispecific antibodies (BsAbs) and ADCs. The company’s innovative platform, DITAC, is designed to enhance the development of ADCs for various cancer indications. Adcendo, on the other hand, specializes in the research and development of novel ADCs for the treatment of cancers, with a focus on leveraging innovative technologies to improve patient outcomes.
Adcendo’s Financing and Development
Adcendo raised EUR 51 million (USD 54.1 million) in a Series A financing round in 2021, with investors including Novo Holdings, Ysios Capital, RA Capital Management, HealthCap, and Gilde Healthcare. This significant funding underscores Adcendo’s commitment to advancing its pipeline of ADCs and addressing significant unmet needs in oncology.
Future Outlook
The technology license agreement between Duality Biologics and Adcendo highlights the growing collaboration between innovative biotech companies to address challenging oncology indications. By leveraging Duality’s DITAC platform, Adcendo aims to enhance the development of its uPARAP program, potentially offering new treatment options for patients with mesenchymal tumors. This partnership underscores the commitment of both companies to advancing cancer therapies and improving patient care.-Fineline Info & Tech
